

Coronavirus and COVID-19

Proof of Vaccination as Defined in the COVID-19 Protective Measures Exemption Directive and the Directive on Coronavirus Entry Regulations

As of 15 January 2022, the following criteria apply to proof of vaccination as defined in the COVID-19 Protective Measures Exceptions Ordinance (SchAusnahmV) and the Coronavirus Entry Ordinance (CoronaEinreiseV).

Changes to the criteria will be posted here as soon as reasonably possible.

Pursuant to section 2 sentence 3 of the SchAusnahmV and section 2 sentence 10 of the CoronaEinreiseV, proof of complete vaccination protection against the coronavirus SARS-CoV-2 exists if the underlying vaccinations correspond to the requirements published by the Paul-Ehrlich-Institut. These requirements, published in consultation with the Robert Koch-Institut and taking currently available medical information into account, must be met with respect to the following criteria:

- a) the vaccine used,
- b) the number of individual vaccinations required for complete vaccination protection,
- c) any booster vaccinations required for continued full vaccination protection,
- d) the length of time
 - a) that must pass after vaccination for complete vaccination protection and
 - b) that must not be exceeded between individual vaccinations and booster vaccinations.

The following vaccines can be used in the following combinations for full vaccination protection.

Requirements for full vaccination protection with a vaccine

Vaccine	Marketing Authorisation Holder	Number of vaccine doses for complete vaccination
Comirnaty Authorisation No. EU/1/20/1528	BioNTech Manufacturing GmbH	2
Spikevax Authorisation No. EU/1/20/1507	Moderna Biotech Spain, S.L.	2
Vaxzevria Authorisation No. EU/1/21/1529	AstraZeneca AB, Schweden	2
COVID-19 Vaccine Janssen Authorisation No. EU/1/20/1525	Janssen-Cilag International NV	2

Requirements for complete vaccination protection with different vaccines (heterologous vaccination schedule)

Vaccination 1	Vaccination 2	Number of vaccine doses for complete vaccination
Vaxzevria Authorisation No. EU/1/21/1529	Comirnaty Authorisation No. EU/1/20/1528	2
Vaxzevria Authorisation No. EU/1/21/1529	Spikevax Authorisation No. EU/1/20/1507	2
Comirnaty Authorisation No. EU/1/20/1528	Spikevax Authorisation No. EU/1/20/1507	2
Spikevax Authorisation No. EU/1/20/1507	Comirnaty Authorisation No. EU/1/20/1528	2
COVID-19 Vaccine Janssen Authorisation No. EU/1/20/1525	Comirnaty Authorisation No. EU/1/20/1528	2
COVID-19 Vaccine Janssen Authorisation No. EU/1/20/1525	Spikevax Authorisation No. EU/1/20/1507	2

List of marketing authorisations and vaccine product names in third countries (outside the EU and EEA)

Versions of EU-authorized vaccines authorised abroad (original or licensed productions) are equivalent to the named EU-authorized vaccines as proof of vaccination protection. For more information, please refer to the list below.

Comirnaty

State / Community of States / Organisation (German notation)	Product Name
Albanien	COMIRNATY
Algerien	Pfizer-BioNTech COVID-19 vaccine
Argentinien	COMIRNATY
Australien	COMIRNATY
Bahrain	Pfizer-BioNTech COVID-19 vaccine
Brasilien	COMIRNATY
Chile	Pfizer-BioNTech COVID-19 vaccine
Costa Rica	Pfizer-BioNTech COVID-19 vaccine
Dominikanische Republik	Pfizer-BioNTech COVID-19 vaccine
Ecuador	Pfizer-BioNTech COVID-19 vaccine
El Salvador	Pfizer-BioNTech COVID-19 vaccine
EU (all member states)	Comirnaty
Georgien	Pfizer-BioNTech COVID-19 vaccine
Honduras	Pfizer-BioNTech COVID-19 vaccine
Hongkong	COMIRNATY
Irak	Pfizer-BioNTech COVID-19 vaccine
Island	Comirnaty
Israel	Pfizer-BioNTech COVID-19 vaccine
Japan	COMIRNATY
Jordanien	Pfizer-BioNTech COVID-19 vaccine
Kanada	Pfizer-BioNTech COVID-19 vaccine
Katar	Pfizer-BioNTech COVID-19 vaccine
Kolumbien	Pfizer-BioNTech COVID-19 vaccine
Kosovo	COMIRNATY
Kuwait	Pfizer-BioNTech COVID-19 vaccine
Libanon	Pfizer-BioNTech COVID-19 vaccine
Liechtenstein	Comirnaty
Macau	COMIRNATY
Malaysia	COMIRNATY
Mexiko	Pfizer-BioNTech COVID-19 vaccine
Moldawien	COMIRNATY
Mongolei	Pfizer-BioNTech COVID-19 vaccine
Neuseeland	COMIRNATY
Nordmazedonien	COMIRNATY
Norwegen	Comirnaty
Oman	Pfizer-BioNTech COVID-19 vaccine
Pakistan	COMIRNATY
Palästina	COMIRNATY
Panama	Pfizer-BioNTech COVID-19 vaccine
Paraguay	Pfizer-BioNTech COVID-19 vaccine
Peru	COMIRNATY
Philippinen	Pfizer-BioNTech COVID-19 vaccine
Ruanda	COMIRNATY
Saudi-Arabien	Pfizer-BioNTech COVID-19 vaccine
Schweiz	COMIRNATY
Serbien	COMIRNATY
Singapur	Pfizer-BioNTech COVID-19 vaccine
Sri Lanka	COMIRNATY

State / Community of States / Organisation (German notation)	Product Name
Südafrika	COMIRNATY
Südkorea	COMIRNATY
Swasiland	COMIRNATY
Tunesien	Pfizer-BioNTech COVID-19 vaccine
Türkei	Pfizer-BioNTech COVID-19 vaccine
Ukraine	COMIRNATY
Uruguay	Pfizer-BioNTech COVID-19 vaccine
USA	Pfizer-BioNTech COVID-19 vaccine
Vereinigte Arabische Emirate	Pfizer-BioNTech COVID-19 vaccine
Vereinigtes Königreich	Pfizer-BioNTech COVID-19 vaccine, COMIRNATY
Vietnam	COMIRNATY

COVID-19 Vaccine Janssen

State / Community of States / Organisation (German notation)	Product Name
Afrikanische Union	COVID-19 Vaccine Janssen
Angola	COVID-19 Vaccine Janssen
Äthiopien	COVID-19 Vaccine Janssen
Bahrain	COVID-19 Vaccine Janssen
Botswana	COVID-19 Vaccine Janssen
Brasilien	Janssen COVID-19 Vaccine / Vacina covid-19 (recombinante)
Cabo Verde	COVID-19 Vaccine Janssen
Chile	COVID-19 Vaccine Janssen
Dem. Republik Kongo	COVID-19 Vaccine Janssen
EU (all member states)	COVID-19 Vaccine Janssen
Gambia	COVID-19 Vaccine Janssen
Ghana	COVID-19 Vaccine Janssen
Guinea-Bissau	COVID-19 Vaccine Janssen
Island	COVID-19 Vaccine Janssen
Jordanien	COVID-19 Vaccine Janssen
Kanada	Janssen COVID-19 Vaccine
Katar	COVID-19 Vaccine Janssen
Kolumbien	Janssen COVID-19 Vaccine / COVID-19 Vaccine Janssen
Kongo	COVID-19 Vaccine Janssen
Kuwait	COVID-19 Vaccine Janssen
Lesotho	COVID-19 Vaccine Janssen
Liberia	COVID-19 Vaccine Janssen
Libyen	COVID-19 Vaccine Janssen
Liechtenstein	COVID-19 Vaccine Janssen
Madagaskar	COVID-19 Vaccine Janssen
Malawi	COVID-19 Vaccine Janssen
Malaysia	COVID-19 Vaccine Janssen Suspension for Injection
Mali	COVID-19 Vaccine Janssen
Mexiko	Janssen COVID-19 Vaccine / COVID-19 Vaccine Janssen
Namibia	COVID-19 Vaccine Janssen
Nigeria	COVID-19 Vaccine Janssen
Norwegen	COVID-19 Vaccine Janssen

State / Community of States / Organisation (German notation)	Product Name
Philippinen	Janssen COVID-19 Vaccine
Republik Korea	COVID-19 Vaccine Janssen
Ruanda	COVID-19 Vaccine Janssen
Sambia	COVID-19 Vaccine Janssen
Sao Tome und Principe	COVID-19 Vaccine Janssen
Saudi-Arabien	COVID-19 Vaccine Janssen
Schweiz	COVID-19 Vaccine Janssen
Senegal	COVID-19 Vaccine Janssen
Südafrika	COVID-19 Vaccine Janssen
Thailand	COVID-19 Vaccine Janssen / Janssen COVID-19 Vaccine
Togo	COVID-19 Vaccine Janssen
Tunesien	COVID-19 Vaccine Janssen
USA	Janssen COVID-19 Vaccine
Vereinigtes Königreich	COVID-19 Vaccine Janssen
WHO	COVID-19 Vaccine Janssen
Zentralafrikanische Republik	COVID-19 Vaccine Janssen

Spikevax (formerly: COVID-19 Vaccine Moderna)

State / Community of States / Organisation (German notation)	Product Name
Botswana	Covid-19 Vaccine Moderna Dispersion for injection
Brunei	Moderna Covid-19 Vaccine (mRNA-1273 Vaccine)
EU (all member states)	Spikevax (formerly: COVID-19 Vaccine Moderna)
Island	Spikevax (formerly: COVID-19 Vaccine Moderna)
Israel	Covid-19 Vaccine Moderna Dispersion for injection
Japan	Covid-19 Vaccine Moderna Intramuscular injection
Jordanien	Covid-19 Vaccine Moderna
Kanada	Covid-19 Vaccine Moderna Dispersion for injection
Katar	Covid-19 Vaccine Moderna Dispersion for injection
Liechtenstein	Spikevax (formerly: COVID-19 Vaccine Moderna)
Norwegen	Spikevax (formerly: COVID-19 Vaccine Moderna)
Paraguay	n/a
Philippinen	Covid-19 Vaccine Moderna
Schweiz	Covid-19 Vaccine Moderna Dispersion for injection
Singapur	Covid-19 Vaccine Moderna Dispersion for injection
Südkorea	Covid-19 Vaccine Moderna
Taiwan	Moderna Covid-19 Vaccine
Thailand	Covid-19 Vaccine Moderna
USA	Moderna Covid-19 Vaccine Suspension for injection
Vereinigtes Königreich	Covid-19 Vaccine Moderna Dispersion for injection
WHO	Covid-19 Vaccine Moderna

Nuvaxovid (NVX-CoV2373)

State / Community of States / Organisation (German notation)	Product Name
EU (all member states)	Nuvaxovid
Indonesien	Covovax
Philippinen	Covovax
WHO	Covovax

Vaxzevria (formerly: COVID-19 Vaccine AstraZeneca)

State / Community of States / Organisation (German notation)	Product Name	Company
Ägypten	Covishield	Serum Institute of India (AstraZeneca licensee)
Argentinien	Covid-19 Vaccine, ASTRAZENECA ®	AstraZeneca
Argentinien	Covishield	Serum Institute of India (AstraZeneca licensee)
Australien	COVID-19 Vaccine AstraZeneca	AstraZeneca
Bahrain	R-CoVI	R-PHARM (AstraZeneca licensee)
Bahrain	Covishield	Serum Institute of India (AstraZeneca licensee)
Bangladesh	Covishield	Serum Institute of India (AstraZeneca licensee)
Botswana	Covishield	Serum Institute of India (AstraZeneca licensee)
Brasilien	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Brasilien	Covid-19 vaccine (recombinant)	FUNDAÇÃO Instituto OSWALDO CRUZ (FIOCRUZ) (AstraZeneca licensee)
Brasilien	Covishield	Serum Institute of India (AstraZeneca licensee)
Brunei	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Chile	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Costa Rica	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Dominikanische Republik	Covid-19 Vaccine AstraZeneca	AstraZeneca
Dominikanische Republik	Covishield	Serum Institute of India (AstraZeneca licensee)
Dubai (UAE)	R-CoVI	R-PHARM (AstraZeneca licensee)
Ecuador	Vacuna AstraZeneca COVID-19 / Covid-19 Vaccine AstraZeneca	AstraZeneca
El Salvador	COVID-19 Vaccine AstraZeneca	AstraZeneca
El Salvador	Covishield	Serum Institute of India (AstraZeneca licensee)
EU (alle Mitgliedstaaten)	Vaxzevria (ehemals: COVID-19 Vaccine AstraZeneca)	AstraZeneca
Gambia	Covishield	Serum Institute of India (AstraZeneca licensee)
Ghana	Covishield	Serum Institute of India (AstraZeneca licensee)
Honduras	COVID-19 Vaccine AstraZeneca	AstraZeneca
Indien	Covishield	Serum Institute of India (AstraZeneca licensee)
Indonesien	COVID-19 Vaccine AstraZeneca	AstraZeneca
Iran	R-CoVI	R-PHARM (AstraZeneca licensee)
Island	Vaxzevria (ehemals: COVID-19 Vaccine AstraZeneca)	AstraZeneca
Israel	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Japan	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Jordanien	R-CoVI	R-PHARM (AstraZeneca licensee)
Jordanien	Covishield	Serum Institute of India (AstraZeneca licensee)
Kanada	AstraZeneca COVID-19 Vaccine (AZD1222) COVISHIELD Vaccine	AstraZeneca
Kenia	Covishield	Serum Institute of India (AstraZeneca licensee)
Kolumbien	Covid-19 Vaccine AstraZeneca	AstraZeneca

State / Community of States / Organisation (German notation)	Product Name	Company
Kuwait	R-CoVI	R-PHARM (AstraZeneca licensee)
Kuwait	Covishield	Serum Institute of India (AstraZeneca licensee)
Libanon	R-CoVI	R-PHARM (AstraZeneca licensee)
Liechtenstein	Vaxzevria (ehemals: COVID-19 Vaccine AstraZeneca)	AstraZeneca
Macau	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Malaysia	COVID-19 Vaccine AstraZeneca	AstraZeneca
Malediven	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Malediven	Covishield	Serum Institute of India (AstraZeneca licensee)
Marokko	R-CoVI	R-PHARM (AstraZeneca licensee)
Marokko	Covishield	Serum Institute of India (AstraZeneca licensee)
Mexiko	Vacuna AstraZeneca COVID-19	AstraZeneca
Mongolei	R-CoVI	R-PHARM (AstraZeneca licensee)
Montenegro	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Myanmar	Covishield	Serum Institute of India (AstraZeneca licensee)
Namibia	Covishield	Serum Institute of India (AstraZeneca licensee)
Nauru	Covishield	Serum Institute of India (AstraZeneca licensee)
Nepal	Covishield	Serum Institute of India (AstraZeneca licensee)
Neuseeland	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Nicaragua	Covishield	Serum Institute of India (AstraZeneca licensee)
Nigeria	Covishield	Serum Institute of India (AstraZeneca licensee)
Norwegen	Vaxzevria (ehemals: COVID-19 Vaccine AstraZeneca)	AstraZeneca
Oman	R-CoVI	R-PHARM (AstraZeneca licensee)
Oman	Covishield	Serum Institute of India (AstraZeneca licensee)
Pakistan	Covishield	Serum Institute of India (AstraZeneca licensee)
Palästina	R-CoVI	R-PHARM (AstraZeneca licensee)
Palästina	Covishield	Serum Institute of India (AstraZeneca licensee)
Panama	COVID-19 Vaccine AstraZeneca	AstraZeneca
Philippinen	COVID-19 Vaccine AstraZeneca	AstraZeneca
Ruanda	Covishield	Serum Institute of India (AstraZeneca licensee)
Saudi-Arabien	Covishield	Serum Institute of India (AstraZeneca licensee)
Schweiz	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Senegal	Covishield	Serum Institute of India (AstraZeneca licensee)
Serbien	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Singapur	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Sri Lanka	Covishield	Serum Institute of India (AstraZeneca licensee)
Südafrika	Covishield	Serum Institute of India (AstraZeneca licensee)
Südkorea	AstraZeneca Korea COVID-19 Vaccine	AstraZeneca
Taiwan	COVID-19 Vaccine AstraZeneca	AstraZeneca
Thailand	COVID-19 Vaccine AstraZeneca	AstraZeneca
Turkmenistan	R-CoVI	R-PHARM (AstraZeneca licensee)
Ukraine	Covishield	Serum Institute of India (AstraZeneca licensee)
Ukraine	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Ungarn	Astra ChAdOx1 S	AstraZeneca
Uruguay	COVID-19 Vaccine AstraZeneca	AstraZeneca
Vereinigtes Königreich	Covid-19 Vaccine AstraZeneca/Vaxzevria	AstraZeneca
Vietnam	COVID-19 Vaccine AstraZeneca	AstraZeneca
WHO	COVID-19 Vaccine AstraZeneca	AstraZeneca

WHO EUL (Emergency Use Listing)

Product Name	Company
AZD1222	AstraZeneca
BNT162b2/COMIRNATY, Tozinameran (INN)	BioNTech/Pfizer
Covishield (ChAdOx1_nCoV-19)	Serum Institute of India (AstraZeneca licensee)
Covovax	Novavax
mRNA-1273	Moderna

List of authorisations and vaccine product names in third countries (outside the EU and EEA) - As of 21 December 2021

[SharedDocs/Downloads/EN/newsroom-en/dossiers/namen-covid-19-impfstoffe-ausland-en.html;jsessionid=2B23AB46C75FoC599966BE1049E4A09F.intranet221?nn=164146]

The list is provided for informational purposes and does not claim to be complete. The person wishing to enter the country is responsible for providing proof of complete vaccination protection with a recognized, EU-authorized vaccine as defined by the Ordinance on Coronavirus Entry Regulations.

Time interval after vaccination for complete vaccination protection

Fourteen days must have passed since the last required vaccination in order for the vaccination to be considered complete.

Exceptional circumstances justifying full vaccination protection with a single dose of vaccine

Notwithstanding the requirements above, a single dose of vaccine with any of the vaccines listed above is considered sufficient if

- the person concerned has physical or digital proof in German, English, French, Italian or Spanish of a positive antibody test carried out on them and this test was carried out at a time when the person concerned had **not yet received a vaccination** against COVID-19. The laboratory diagnostic findings must have come from a laboratory that works in accordance with the guidelines of the German Medical Association on Quality Assurance in Medical Laboratory Examinations (RiLiBÄK) or that is accredited in accordance with DIN EN ISO 15189. In this case, the 14-day post-vaccination period does not apply.
- the person concerned has proof of a previous infection with the SARS-CoV-2 coronavirus. Proof of infection requires proof of a test based on laboratory diagnostics using nucleic acid detection laboratory diagnostics (PCR, POC-PCR or other nucleic acid amplification technology methods) and this test must have been carried out at a time when the person concerned had **not yet been vaccinated** against COVID-19. If the infection occurred before the first vaccination was given, the required 14-day post vaccination period does not apply.
- the person concerned was infected with the SARS-CoV-2 coronavirus **after receiving a single vaccine dose**. Proof of infection requires proof of a test based on laboratory diagnostics using nucleic acid detection (PCR, POC-PCR or other nucleic acid amplification technology methods). If the infection occurred after the first vaccine dose was administered, 28 days must have passed since the infection was first detected.

Note

Information on booster vaccinations and the corresponding time intervals has not yet been published.

As of

15 January 2022

Further Information

Ordinance amending the COVID-19 Protective Measures Exceptions Ordinance and the Ordinance on Coronavirus Entry Regulations of 14 January 2022 (German only)
[<https://www.bundesanzeiger.de/pub/publication/yW2hBRkcEPpvCQIb8IT/content/yW2hBRkcEPpvCQIb8IT/BAnz%20AT%2014.01.2022%20V1.pdf?inline>]

Content

- Role of the Paul-Ehrlich-Institut** [EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=2B23AB46C75FoC599966BE1049E4A09F.intranet221?nn=164146&cms_pos=1]
- COVID-19 Vaccines** [EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=2B23AB46C75FoC599966BE1049E4A09F.intranet221?nn=164146&cms_pos=2]

3. **Proof of Vaccination as Defined in the COVID-19 Protective Measures Exemption Directive and the Directive on Coronavirus Entry Regulations**
 4. **FAQ Coronavirus** [[EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=2B23AB46C75FoC599966BE1049E4A09F.intranet221?nn=164146&cms_pos=4](https://www.pei.de/EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=2B23AB46C75FoC599966BE1049E4A09F.intranet221?nn=164146&cms_pos=4)]
 5. **Biomedicines** [[EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=2B23AB46C75FoC599966BE1049E4A09F.intranet221?nn=164146&cms_pos=5](https://www.pei.de/EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=2B23AB46C75FoC599966BE1049E4A09F.intranet221?nn=164146&cms_pos=5)]
 6. **Safety of COVID-19 Vaccines** [[EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=2B23AB46C75FoC599966BE1049E4A09F.intranet221?nn=164146&cms_pos=6](https://www.pei.de/EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=2B23AB46C75FoC599966BE1049E4A09F.intranet221?nn=164146&cms_pos=6)]
 7. **Research Work** [[EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=2B23AB46C75FoC599966BE1049E4A09F.intranet221?nn=164146&cms_pos=7](https://www.pei.de/EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=2B23AB46C75FoC599966BE1049E4A09F.intranet221?nn=164146&cms_pos=7)]
 8. **SARS-CoV-2 Test Systems** [[EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=2B23AB46C75FoC599966BE1049E4A09F.intranet221?nn=164146&cms_pos=8](https://www.pei.de/EN/newsroom/dossier/coronavirus/coronavirus-content.html;jsessionid=2B23AB46C75FoC599966BE1049E4A09F.intranet221?nn=164146&cms_pos=8)]
-



The Paul-Ehrlich-Institut is an Agency of the German Federal Ministry of Health.
Its research and control activities promote the quality, efficacy and safety of biological medicinal products.